Synopsys, Inc. or Manhattan Associates, Inc.: Who Invests More in Innovation?

Synopsys vs. Manhattan: A Decade of R&D Investment

__timestampManhattan Associates, Inc.Synopsys, Inc.
Wednesday, January 1, 201448953000718768000
Thursday, January 1, 201553859000776229000
Friday, January 1, 201654736000856705000
Sunday, January 1, 201757704000908841000
Monday, January 1, 2018718960001084822000
Tuesday, January 1, 2019876080001136932000
Wednesday, January 1, 2020842760001279022000
Friday, January 1, 2021976280001504823000
Saturday, January 1, 20221118770001680379000
Sunday, January 1, 20231268140001946813000
Monday, January 1, 20241376890002082360000
Loading chart...

Unleashing insights

Innovation Investment: A Tale of Two Companies

In the ever-evolving tech landscape, innovation is the lifeblood of success. Synopsys, Inc. and Manhattan Associates, Inc. are two giants in their respective fields, but their investment in research and development (R&D) tells a compelling story. Over the past decade, Synopsys has consistently outpaced Manhattan Associates in R&D spending, with a staggering 1,500% more investment in 2023 alone. This trend highlights Synopsys's commitment to staying at the forefront of technological advancements. From 2014 to 2024, Synopsys's R&D expenses grew by nearly 190%, reflecting its strategic focus on innovation. Meanwhile, Manhattan Associates, while increasing its R&D spending by approximately 180%, remains more conservative in its approach. This disparity underscores the different strategic priorities of these companies, with Synopsys aggressively pursuing innovation to maintain its competitive edge.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
28 Jan 2025